Summary We have examined the killing effect of 4-S-cysteaminylphenol (4-S-CAP), a newly synthesised melanin precursor, on B16 melanoma cell lines possessing different melanin-producing activities and found it to be particularly effective in heavily melanised melanoma cells, but less so in moderately melanised melanoma cells, and having no effect on amelanotic melanoma cells and nonmelanoma cells. Thus, it was found that the killing effect of 4-S-CAP is highly dependent upon the synthesis of melanin and tyrosinase in melanoma cells, suggesting that 4-S-CAP may become toxic to melanoma cells only after oxidation by tyrosinase. The killing activity of 4-S-CAP also was found to be associated with a profound inhibition of the thymidine incorporation in pigmented melanoma cells, as compared to the uridine and leucine incorporation. Further, the inhibition of DNA synthesis was most pronounced in heavily melanised melanoma cells, less so in moderately melanised melanoma cells, and not seen in amelanotic melanoma cells. As a possible mechanism that might account for this action, it may be that 4-S-CAP is oxidised by tyrosinase to the o-quinone form via the catechol derivative and that some of the quinones then conjugate with sulfhydryl enzymes including DNA polymerase, thus exerting a killing activity for pigmented melanoma cells. Thus, 4-S-CAP appears to provide a new, effective cytotoxic agent for rational chemotherapy of malignant melanomas.
Many attempts have been made to develop a rational chemotherapy for malignant melanomas by utilising one of the unique biochemical properties of such melanomas, their melanin synthesis (Pawelek, 1976) . This consists of the conversion of tyrosine to dopa and dopaquinone in the presence of tyrosinase (EC 1.14.18.1). In a malignant melanoma, the synthesis of melanin is highly elevated because of a marked increase of tyrosinase activity (Pawelek et al., 1973; Pawelek, 1976) . Previously, Wick et al. (1977 Wick et al. ( , 1978 have shown that catecholic compounds related to dopa and dopamine possess significant antitumoral activities against melanomas in vitro and in vivo. However, a major drawback in using catechols as chemotherapeutic agents is that they also possess certain degrees of systemic toxicity that may result from an autooxidation of the catechols and a concomitant production of active oxygen species (Graham et al., 1978a) . As a result, some catechols exhibit less of an antimelanoma effect than the corresponding phenols (Rosowsky et al., 1979; Wick et al., 1980) . Thus, a rational approach to overcome this difficulty would seem to be to use phenolic compounds that are the immediate precursors of catecholic compounds. Further, the phenol could be hydroxylated by tyrosinase to form catechols within the melanoma cells.
Therefore, in a search for more effective melanocytotoxic agents, we have synthesised various phenolic compounds as substrates for tyrosinase, and have demonstrated that, among these synthetic compounds, 4-S-cysteaminylphenol (4-S-CAP) possesses the most significant effect in inhibiting the growth of melanomas in experimental mice (Miura et al., 1987) . Pursuing our quest further, in this report, we have evaluated the killing effects of 4-S-CAP on B16 melanoma cell lines possessing different melanin-producing activities, and have authors (Dr S. Ito), and the details of this chemical synthesis have been reported previously (Miura et al., 1987) . The drug solution was freshly prepared in a Ham's F-10 medium (Gibco, Grand Island, NY) just before use at the beginning of each experiment.
Cells
Four sublines of B16-XI melanoma cells, maintained in our laboratory, were used. The pigment-producing capability of the four cell lines was characterised as being capable of heavy (B16-XID), moderate (Bl 6-XIT, B1 6-XIW), or no pigment production (Bi6-XIA), and all were derived originally from the B16-XI cell line (Oikawa et al., 1987) . L929 mouse fibroblast cells, CHO Chinese hamster ovary cells, and HeLa S3 cells were gifts from Aichi Cancer Center Research Institute, Nagoya, Japan. These cell lines have been maintained in the Ham's F-10 medium, supplemented with 10% calf serum (Flow Laboratories, Rockville, MD), penicillin (100 U ml-'), and streptomycin (100 ytg ml-'), and incubated in a humidified atmosphere of 95% air-5% CO2 at 37°C. .01 values were measured as being the 4-S-CAP dose (tg ml-') required to reduce survival after 1 h exposure to 0.1 and 0.01, respectively.
Incorporation of labelled precursors into macromolecules
The effect of 4-S-CAP on the macromolecular synthesis was determined by a method similar to that used by Wick (1978) . Cells (1 x 105) were plated in multiwell tissue culture trays (Linbro Plastics, Vineland, NJ). After a 48 h incubation, exponentially-growing cultures were aspirated and washed, and 1 ml of a culture medium containing 2 gLCi ml1 l amounts of either 3H thymidine (specific activity, 2 Ci mmol-'), 5-3H uridine (specific activity, 25 Ci mmol-') or 3H leucine (specific activity, 41 Ci mmol ') (New England Nuclear, Boston, Mass.) and 4-S-CAP were added. After 1 h incubation at 37'C, the medium was removed. Then, the cells were washed once with phosphate buffered saline (PBS, pH 7.2), and 1 ml of 10% trichloroacetic acid was added. The resulting precipitate was washed three times with PBS, after which 0.5 ml of I N KOH was added. After digestion at 37°C for 4 h, a portion was added to a scintillation fluid (Aquasol-II; New England Nuclear) and then counted with a Packard Tri-Carb 460CD liquid scintillation spectrometer (Packard Instrument Co., Downers Grove, Ill). Values are expressed as a percentage of inhibition, as compared to the controls, and represent a mean ± s.d. of three separate experiments.
Cell kinetics study
The cell cycle distribution of the melanoma cells treated with 4-S-CAP was determined from DNA histograms measured by flow cytometry. Exponentially-growing cells were incubated with different concentrations of 4-S-CAP at 37'C for I h, after which the 4-S-CAP was removed by changing the culture medium. After a 24 h incubation, the cells were trypsinised from the dish and washed twice with PBS. The cells then were stained with a mixture of propidium iodide (50 pg ml-'; Calbiochem, San Diego, CA), RNAase (100Iggml-; RNAase A, 4396 U mg-1, Worthington Biochemical Corp, Freehold, NJ), and Triton-X-100 (0.2%) in PBS for 10min (Taylor, 1980) . The DNA count was assayed by flow cytometry, using a FACScan (Becton-Dickinson, Sunnyvale, CA), with a collection of fluorescence emissions longer than 590 nm. One x I05 cells were counted and the distribution histograms of the fluorescence intensity in linear scale were obtained. The cell cycle analysis by DNA distribution was performed by using the 'CCANA 1' program reported by Dean (1980) , and the populations during the GI, S, and G2-M phases were calculated. Each data value given represents a mean ± s.d. of three separate experiments. The same experiments and subsequent analyses were done for the untreated controls.
Results

Killing effects of 4-S-CAP
The dose-response survival curves of the four B16-XI melanoma cell lines after I h treatment with 4-S-CAP are shown in Figure 1 , and the Do., and D0.0, values of the 4-S-CAP for each cell line are summarised in Table I . It was found that 4-S-CAP demonstrated a remarkably potent killing effect on the heavily melanised B16-XID melanoma cells, and that the Do., and D001 values were 7.7 ± 2.7 gg ml-' and 15.5 ± 3.7 gg ml-', respectively. In contrast, the same treatment with 4-S-CAP resulted in no significant killing effect on the completely amelanotic B 1 6-XIA melanoma cells up to the concentration of 500 gig ml-'. Similarly, 4-S-CAP had no significant killing effect on three nonmelanoma cell lines (0) treatment with 4-S-CAP on the completely amelanotic B16-XIA melanoma cells showed no inhibition of thymidine incorporation up to the concentration of 100pgml-'. For the moderately melanised B16-XIT cells, 4-S-CAP showed an intermediate inhibition of thymidine incorporation that fell between the response seen in the B16-XID and B16-XIA cells, and the percentage of inhibition at the concentration of 10 g ml-' was 63.6 ± 1.7%. Next, the effects of 4-S-CAP on the radiolabelled thymidine, uridine, and leucine incorporation by the heavily melanised B16-XID melanoma cells were examined (Table  II) . Compared to the inhibition of the thymidine incorporation seen, the inhibition of uridine and leucine was slight up to the concentration of 100Itgml-'. Thus, the inhibition of thymidine incorporation was found to be the most sensitive index of the killing effect of 4-S-CAP, with lesser effects observed upon uridine and leucine incorporation.
Inhibition of cell cycle progression After I h treatment with 4-S-CAP, the B16-XID cells percentages during the G,, S, and G2-M phases were plotted for the concentrations used (Figure 3 ). There was an accumulation of S cells noted that depended upon the concentration of the 4-S-CAP, in association with a simultaneous decrease of G, cells. The G2-M cells also were seen to accumulate slightly in a larger concentration. The accumulation of S-phase cells, depending upon the concentration, appears to be related to the inhibition of the thymidine incorporation seen in the B16-XID melanoma cells.
Discussion
Our results have demonstrated that 4-S-CAP has a remarkably potent killing activity for pigmented melanoma cells. This killing effect was highly dependent upon the degrees of melanin or tyrosinase synthesis in the melanoma cells, and it had no killing effect on amelanotic melanoma cells and nonmelanoma cells. Therefore, it may be that 4-S-CAP becomes toxic to melanoma cells only after oxidation by tyrosinase. Our previous report has indicated that 4-S-CAP is a much better substrate for tyrosinase than L-tyrosine, and that 4-S-CAP is oxidised to the corresponding o-quinone form, which conjugates covalently with proteins through cysteine residues . Thus, the killing effect of 4-S-CAP may be exerted on the pigmented melanoma cells through its conversion to an o-quinone form and a subsequent scavenging action on sulfhydryl groups.
The killing activity of 4-S-CAP was found to be associated with a profound inhibition of the thymidine incorporation, as measured during exposure to the drug, with the greatest inhibition seen in the heavily melanised melanoma cells. Uridine and leucine incorporations were found to be largely unaffected by 4-S-CAP. Thus, 4-S-CAP seems to exert its cell-killing activity for melanoma cells primarily through the inhibition of the DNA synthesis in comparison to RNA and protein synthesis.
In the catecholic compounds, the inhibition of DNA polymerase has been postulated as being one site of action that was based upon the ability of o-quinone forms to act as sulfhydryl reagents (Wick et al., 1977; Wick, 1978) . This hypothesis is supported by the fact that o-quinones have a marked affinity for DNA polymerase alpha (Graham et al., 1978b) and that L-dopa inhibits the activity of DNA polymerase alpha only in the presence of tyrosinase (Wick, 1980) . As a possible mechanism of 4-S-CAP action, therefore, it may be that 4-S-CAP is oxidised by tyrosinase to the oquinone form via the catechol derivative and that some of the quinones conjugate with sulfhydryl enzymes including DNA polymerase alpha, thus triggered its killing activity towards pigmented melanoma cells (Figure 4 ). 4-S-CAP is a stable compound in comparison to catecholic compounds, and it can be activated by conversion to oquinone form only in the presence of tyrosinase. In a malignant melanoma, the synthesis of melanin is highly elevated because of a marked increase of tyrosinase activity. Thus, our finding of this 4-S-CAP selective killing effect on melanoma cells in which the melanin and tyrosinase synthesis is highly active may favour its chemotherapeutic use for treating malignant melanomas. Further, the synthesis of tyrosinase and melanin, even in amelanotic melanoma cells, can be enhanced by the administration of a melanocytestimulating hormone (Pawelek, 1976; Siegrist, 1989) . Thus, 4-S-CAP appears to provide a new, effective cytotoxic agent for a rational chemotherapy that can ameliorate malignant melanomas.
